Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Biomed Res Int. 2022 Nov 22;2022:6189254. doi: 10.1155/2022/6189254. eCollection 2022.
Coronavirus illness 2019 is a significant worldwide health danger that began with severe acute respiratory syndrome coronavirus two infections. It is the largest pandemic of our lifetime to date, affecting millions of people and crippling economies globally. There is currently no viable therapy for this devastating condition. The fast spread of SARS-CoV-2 underlines the critical need for favorable treatments to prevent SARS-CoV-2 infection and dissemination. Regulating the upstream cytokine release might be a possible method for COVID-19 therapy. We propose that more consideration be paid to the dysregulated IFN-I release in COVID-19 and that cGAS and STING be considered therapeutic targets for avoiding cytokine storms and as critical components in host antiviral defense mechanisms.
2019 年冠状病毒病是一种严重的全球健康威胁，它始于严重急性呼吸系统综合症冠状病毒 2 型感染。这是迄今为止我们一生中最大的一次大流行，影响了数百万人，并使全球经济陷入瘫痪。目前，针对这种破坏性疾病还没有可行的治疗方法。SARS-CoV-2 的快速传播突显了迫切需要寻找有利的治疗方法来预防 SARS-CoV-2 的感染和传播。调节上游细胞因子的释放可能是 COVID-19 治疗的一种可能方法。我们提出，应该更多地考虑 COVID-19 中失调的 IFN-I 释放，以及 cGAS 和 STING 作为避免细胞因子风暴的治疗靶点，并作为宿主抗病毒防御机制的关键组成部分。
